Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine

Huma Qureshi, Zhong Min Ma, Ying Huang, Gregory Hodge, Michael A. Thomas, Janet Dipasquale, Veronique Desilva, Linda Fritts, Andrew J. Bett, Danilo R. Casimiro, John W. Shiver, Marjorie Robert-Guroff, Michael N. Robertson, Michael B. Mcchesney, Peter B. Gilbert, Chris J Miller

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The Step Trial showed that the MRKAd5 HIV-1 subtype B Gag/Pol/Nef vaccine did not protect men from HIV infection or reduce setpoint plasma viral RNA (vRNA) levels but, unexpectedly, it did modestly enhance susceptibility to HIV infection in adenovirus type 5 (Ad5)-seropositive, uncircumcised men. As part of the process to understand the results of the Step Trial, we designed a study to determine whether rhesus macaques chronically infected with a host-range mutant Ad5 (Ad5hr) and then immunized with a replication defective Ad5 SIVmac239 Gag/Pol/Nef vaccine were more resistant or susceptible to SIV infection than unimmunized rhesus macaques challenged with a series of escalating dose penile exposures to SIVmac 251. The Ad5 SIV vaccine induced CD8 + T cell responses in 70% of the monkeys, which is similar to the proportion of humans that responded to the vaccine in the Step Trial. However, the vaccine did not protect vaccinated animals from penile SIV challenge. At the lowest SIV exposure dose (10 3 50% tissue culture infective doses), 2 of 9 Ad5-seropositive animals immunized with the Ad5 SIV vaccine became infected compared to 0 of 34 animals infected in the other animal groups (naive animals, Ad5-seropositive animals immunized with the empty Ad5 vector, Ad5-seronegative animals immunized with the Ad5 SIV vaccine, and Ad5-seronegative animals immunized with the empty Ad5 vector). Penile exposure to more concentrated virus inocula produced similar rates of infection in all animal groups. Although setpoint viral loads were unaffected in Step vaccinees, the Ad5 SIV-immunized animals had significantly lower acute-phase plasma vRNA levels compared to unimmunized animals. Thus, the results of the nonhuman primate (NHP) study described here recapitulate the lack of protection against HIV acquisition seen in the Step Trial and suggest a greater risk of infection in the Ad5-seropositive animals immunized with the Ad5 SIV vaccine. Further studies are necessary to confirm the enhancement of virus acquisition and to discern associated mechanisms.

Original languageEnglish (US)
Pages (from-to)2239-2250
Number of pages12
JournalJournal of Virology
Volume86
Issue number4
DOIs
StatePublished - Feb 2012

Fingerprint

AIDS Vaccines
Adenoviridae
Human immunodeficiency virus 1
Macaca mulatta
HIV-1
Vaccines
vaccines
dosage
SAIDS Vaccines
animals
Viral RNA
HIV infections
HIV Infections
RNA
Viruses
Adenoviridae Infections
viruses
Host Specificity
biological resistance
viral load

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. / Qureshi, Huma; Ma, Zhong Min; Huang, Ying; Hodge, Gregory; Thomas, Michael A.; Dipasquale, Janet; Desilva, Veronique; Fritts, Linda; Bett, Andrew J.; Casimiro, Danilo R.; Shiver, John W.; Robert-Guroff, Marjorie; Robertson, Michael N.; Mcchesney, Michael B.; Gilbert, Peter B.; Miller, Chris J.

In: Journal of Virology, Vol. 86, No. 4, 02.2012, p. 2239-2250.

Research output: Contribution to journalArticle

Qureshi, H, Ma, ZM, Huang, Y, Hodge, G, Thomas, MA, Dipasquale, J, Desilva, V, Fritts, L, Bett, AJ, Casimiro, DR, Shiver, JW, Robert-Guroff, M, Robertson, MN, Mcchesney, MB, Gilbert, PB & Miller, CJ 2012, 'Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine', Journal of Virology, vol. 86, no. 4, pp. 2239-2250. https://doi.org/10.1128/JVI.06175-11
Qureshi, Huma ; Ma, Zhong Min ; Huang, Ying ; Hodge, Gregory ; Thomas, Michael A. ; Dipasquale, Janet ; Desilva, Veronique ; Fritts, Linda ; Bett, Andrew J. ; Casimiro, Danilo R. ; Shiver, John W. ; Robert-Guroff, Marjorie ; Robertson, Michael N. ; Mcchesney, Michael B. ; Gilbert, Peter B. ; Miller, Chris J. / Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. In: Journal of Virology. 2012 ; Vol. 86, No. 4. pp. 2239-2250.
@article{6de6361fbbaf4af7ae71fa7e71ade351,
title = "Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine",
abstract = "The Step Trial showed that the MRKAd5 HIV-1 subtype B Gag/Pol/Nef vaccine did not protect men from HIV infection or reduce setpoint plasma viral RNA (vRNA) levels but, unexpectedly, it did modestly enhance susceptibility to HIV infection in adenovirus type 5 (Ad5)-seropositive, uncircumcised men. As part of the process to understand the results of the Step Trial, we designed a study to determine whether rhesus macaques chronically infected with a host-range mutant Ad5 (Ad5hr) and then immunized with a replication defective Ad5 SIVmac239 Gag/Pol/Nef vaccine were more resistant or susceptible to SIV infection than unimmunized rhesus macaques challenged with a series of escalating dose penile exposures to SIVmac 251. The Ad5 SIV vaccine induced CD8 + T cell responses in 70{\%} of the monkeys, which is similar to the proportion of humans that responded to the vaccine in the Step Trial. However, the vaccine did not protect vaccinated animals from penile SIV challenge. At the lowest SIV exposure dose (10 3 50{\%} tissue culture infective doses), 2 of 9 Ad5-seropositive animals immunized with the Ad5 SIV vaccine became infected compared to 0 of 34 animals infected in the other animal groups (naive animals, Ad5-seropositive animals immunized with the empty Ad5 vector, Ad5-seronegative animals immunized with the Ad5 SIV vaccine, and Ad5-seronegative animals immunized with the empty Ad5 vector). Penile exposure to more concentrated virus inocula produced similar rates of infection in all animal groups. Although setpoint viral loads were unaffected in Step vaccinees, the Ad5 SIV-immunized animals had significantly lower acute-phase plasma vRNA levels compared to unimmunized animals. Thus, the results of the nonhuman primate (NHP) study described here recapitulate the lack of protection against HIV acquisition seen in the Step Trial and suggest a greater risk of infection in the Ad5-seropositive animals immunized with the Ad5 SIV vaccine. Further studies are necessary to confirm the enhancement of virus acquisition and to discern associated mechanisms.",
author = "Huma Qureshi and Ma, {Zhong Min} and Ying Huang and Gregory Hodge and Thomas, {Michael A.} and Janet Dipasquale and Veronique Desilva and Linda Fritts and Bett, {Andrew J.} and Casimiro, {Danilo R.} and Shiver, {John W.} and Marjorie Robert-Guroff and Robertson, {Michael N.} and Mcchesney, {Michael B.} and Gilbert, {Peter B.} and Miller, {Chris J}",
year = "2012",
month = "2",
doi = "10.1128/JVI.06175-11",
language = "English (US)",
volume = "86",
pages = "2239--2250",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine

AU - Qureshi, Huma

AU - Ma, Zhong Min

AU - Huang, Ying

AU - Hodge, Gregory

AU - Thomas, Michael A.

AU - Dipasquale, Janet

AU - Desilva, Veronique

AU - Fritts, Linda

AU - Bett, Andrew J.

AU - Casimiro, Danilo R.

AU - Shiver, John W.

AU - Robert-Guroff, Marjorie

AU - Robertson, Michael N.

AU - Mcchesney, Michael B.

AU - Gilbert, Peter B.

AU - Miller, Chris J

PY - 2012/2

Y1 - 2012/2

N2 - The Step Trial showed that the MRKAd5 HIV-1 subtype B Gag/Pol/Nef vaccine did not protect men from HIV infection or reduce setpoint plasma viral RNA (vRNA) levels but, unexpectedly, it did modestly enhance susceptibility to HIV infection in adenovirus type 5 (Ad5)-seropositive, uncircumcised men. As part of the process to understand the results of the Step Trial, we designed a study to determine whether rhesus macaques chronically infected with a host-range mutant Ad5 (Ad5hr) and then immunized with a replication defective Ad5 SIVmac239 Gag/Pol/Nef vaccine were more resistant or susceptible to SIV infection than unimmunized rhesus macaques challenged with a series of escalating dose penile exposures to SIVmac 251. The Ad5 SIV vaccine induced CD8 + T cell responses in 70% of the monkeys, which is similar to the proportion of humans that responded to the vaccine in the Step Trial. However, the vaccine did not protect vaccinated animals from penile SIV challenge. At the lowest SIV exposure dose (10 3 50% tissue culture infective doses), 2 of 9 Ad5-seropositive animals immunized with the Ad5 SIV vaccine became infected compared to 0 of 34 animals infected in the other animal groups (naive animals, Ad5-seropositive animals immunized with the empty Ad5 vector, Ad5-seronegative animals immunized with the Ad5 SIV vaccine, and Ad5-seronegative animals immunized with the empty Ad5 vector). Penile exposure to more concentrated virus inocula produced similar rates of infection in all animal groups. Although setpoint viral loads were unaffected in Step vaccinees, the Ad5 SIV-immunized animals had significantly lower acute-phase plasma vRNA levels compared to unimmunized animals. Thus, the results of the nonhuman primate (NHP) study described here recapitulate the lack of protection against HIV acquisition seen in the Step Trial and suggest a greater risk of infection in the Ad5-seropositive animals immunized with the Ad5 SIV vaccine. Further studies are necessary to confirm the enhancement of virus acquisition and to discern associated mechanisms.

AB - The Step Trial showed that the MRKAd5 HIV-1 subtype B Gag/Pol/Nef vaccine did not protect men from HIV infection or reduce setpoint plasma viral RNA (vRNA) levels but, unexpectedly, it did modestly enhance susceptibility to HIV infection in adenovirus type 5 (Ad5)-seropositive, uncircumcised men. As part of the process to understand the results of the Step Trial, we designed a study to determine whether rhesus macaques chronically infected with a host-range mutant Ad5 (Ad5hr) and then immunized with a replication defective Ad5 SIVmac239 Gag/Pol/Nef vaccine were more resistant or susceptible to SIV infection than unimmunized rhesus macaques challenged with a series of escalating dose penile exposures to SIVmac 251. The Ad5 SIV vaccine induced CD8 + T cell responses in 70% of the monkeys, which is similar to the proportion of humans that responded to the vaccine in the Step Trial. However, the vaccine did not protect vaccinated animals from penile SIV challenge. At the lowest SIV exposure dose (10 3 50% tissue culture infective doses), 2 of 9 Ad5-seropositive animals immunized with the Ad5 SIV vaccine became infected compared to 0 of 34 animals infected in the other animal groups (naive animals, Ad5-seropositive animals immunized with the empty Ad5 vector, Ad5-seronegative animals immunized with the Ad5 SIV vaccine, and Ad5-seronegative animals immunized with the empty Ad5 vector). Penile exposure to more concentrated virus inocula produced similar rates of infection in all animal groups. Although setpoint viral loads were unaffected in Step vaccinees, the Ad5 SIV-immunized animals had significantly lower acute-phase plasma vRNA levels compared to unimmunized animals. Thus, the results of the nonhuman primate (NHP) study described here recapitulate the lack of protection against HIV acquisition seen in the Step Trial and suggest a greater risk of infection in the Ad5-seropositive animals immunized with the Ad5 SIV vaccine. Further studies are necessary to confirm the enhancement of virus acquisition and to discern associated mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84863116109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863116109&partnerID=8YFLogxK

U2 - 10.1128/JVI.06175-11

DO - 10.1128/JVI.06175-11

M3 - Article

C2 - 22156519

AN - SCOPUS:84863116109

VL - 86

SP - 2239

EP - 2250

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 4

ER -